FORTISBSEFortis Healthcare LtdMediumNeutral
Announced Fri, 29 May · 16:24 IST

Relevant disclosure attached

Mgmt Guided Margin ImprovementAnalyst Day Multiyear TargetsInvestor Communications View source PDF

FORTIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.4%1-day move
₹936.75
prior close
₹933.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0-0.2-0.5-0.4-0.4-0.7+0.5+2.6+5.2+5.0+4.2+1.2
Up moveDown movePending
AI summary

Fortis Healthcare reported FY26 consolidated revenue of INR9,128 crores (+17.3% YoY) with operating EBITDA of INR2,085 crores (+31.3%), translating to 22.8% margin versus 20.4% in FY25. Hospital business grew 19.1% to INR7,773 crores with EBITDA margins improving to 22.2%. Q4 FY26 showed revenue of INR2,365 crores (+17.8%) and PAT of INR271 crores (+44.2% YoY). The company added ~800 beds during the year through acquisitions (People Tree Bengaluru, Shrimann Jalandhar) and brownfield expansions. FY27 guidance: 15%+ hospital revenue growth and 150 basis points EBITDA margin improvement; Diagnostics to achieve 23-24% margins on double-digit revenue growth. IHH Healthcare is planning to increase its stake to 50% with ~INR10,000 crores equity infusion. Key headwinds include CGHS/ECHS drug price capping impact on Punjab hospitals and occupancy pressures at BG Road (55%).

Likely market impact

Strong all-round performance with margin expansion on track. Parent IHH's planned stake increase and INR10,000 crore infusion provides growth capital visibility. Near-term challenges from CGHS pricing and international business dip are manageable given robust domestic growth momentum.